A marriage of two "methusalem"drugs for the treatment of psoriasisαarguments for a pilot trial with metformin as add-on for methotrexate

Dermato-Endocrinology

Volumn 5, Issue 2, 2013, Pages 252-263

  Glossmann, Hartmut ^a   Reider, Norbert ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Amp activated protein kinase; Anti inflammatory; Metformin; Methotrexate; Psoriasis

Indexed keywords

ADENYLATE KINASE; METFORMIN; METHOTREXATE;

DRUG MECHANISM; HUMAN; METABOLIC SYNDROME X; OBESITY; PSORIASIS; REVIEW; T LYMPHOCYTE;

EID: 84885132439     PISSN: 19381972     EISSN: 19381980     Source Type: Journal    
DOI: 10.4161/derm.23874     Document Type: Review

References (149)

1. Li W, Han J, Hu FB, Curhan GC, Qureshi AA. Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. J Invest Dermatol 2012; 132:291-8; PMID:21993559; http://dx.doi.org/10. 1038/jid.2011.319
2. Brauchli YB, Jick SS, Curtin F, Meier CR. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based casecontrol study. J Am Acad Dermatol 2008; 58:421-9; PMID:18194825; http://dx.doi.org/10.1016/j. jaad.2007.11.023
3. Wiley SE, Murphy AN, Ross SA, van der Geer P, Dixon JE. MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc Natl Acad Sci U S A 2007; 104:5318-23; PMID:17376863; http://dx.doi.org/10.1073/ pnas.0701078104
4. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221:176-82; PMID:14799481; http://dx.doi. org/10.1097/00000441- 195102000-00009
5. Bailey CJ, Day C. Metformin:its botanical background. Pract Diabetes Int 2004; 21:115-7; http://dx.doi. org/10.1002/pdi.606
6. Reinwein H. Ueber die therapeutische Verwendbarkeit des Galegins bei Diabetikern. Munch Med Wochenschr 1927; 74:1794-5
7. Dronsfield A, Ellis P. Drug discovery: metformin and the control of diabetes. Education in Chemistry 2011; 185-7
8. Garcia EY. Flumamine, a new synthetic analgesic and anti-flu drug. J Philipp Med Assoc 1950; 26:287-93; PMID:14779282
9. Dasgupta T, Chitnumsub P, Kamchonwongpaisan S, Maneeruttanarungroj C, Nichols SE, Lyons TM, et al. Exploiting structural analysis, in silico screening, and serendipity to identify novel inhibitors of drugresistant falciparum malaria. ACS Chem Biol 2009; 4:29-40; PMID:19146480; http://dx.doi.org/10.1021/ cb8002804
10. Hesse G, Taubmann G. Die Wirkung des Biguanids und seiner Dervate auf den Zuckerstoffwechsel. Naunyn-Schmiedebergs Arch Exp Path Pharmacol 1929; (142):290-308; http://dx.doi.org/10.1007/ BF02000097
11. Fearnley GR, Chakrabarti R. Fibrinolytic treatment of rheumatoid arthritis with phenformin plus ethyloestrenol. Lancet 1966; 2:757-61; PMID:4162320; http:// dx.doi.org/10.1016/S0140-6736(66)90360-6
12. Fearnley GR, Chakrabarti R, Hocking E. PHENFORMIN IN RHEUMATOID ARTHRITIS A FIBRINOLYTIC APPROACH. Lancet 1965; 285:9-13; http://dx.doi.org/10.1016/ S0140-6736(65)90921-9
13. Kersley GD. Phenformin (Dibotin) in polyarthritis. Ann Rheum Dis 1968; 27:374-6; PMID:4875263;
14. Scheurer M, Michel A, Brauch HJ, Ruck W, Sacher F. Occurrence and fate of the antidiabetic drug metformin and its metabolite guanylurea in the environment and during drinking water treatment. Water Res 2012; 46:4790-802; PMID:22770965; http://dx.doi. org/10.1016/j.watres.2012.06.019
15. Eggen T, Lillo C. Antidiabetic II drug metformin in plants: uptake and translocation to edible parts of cereals, oily seeds, beans, tomato, squash, carrots, and potatoes. J Agric Food Chem 2012; 60:6929-35; PMID:22712757; http://dx.doi.org/10.1021/ jf301267c
16. Onken B, Driscoll M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One 2010; 5:e8758; PMID:20090912; http://dx.doi.org/10. 1371/journal.pone.0008758
17. Menendez JA, Vazquez-Martin A. Rejuvenating regeneration: metformin activates endogenous adult stem cells. Cell Cycle 2012; 11:3521-2; PMID:22935702; http://dx.doi.org/10.4161/cc.21878
18. Morales AI, Detaille D, Prieto M, Puente A, Briones E, Arevalo M, et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int 2010; 77:861-9; PMID:20164825; http://dx.doi.org/10.1038/ ki.2010.11
19. Hadi NR, Al-Amran FG, Swadi A. Metformin ameliorates methotrexate-induced hepatotoxicity. J Pharmacol Pharmacother 2012; 3:248-53; PMID:23129960; http://dx.doi.org/10.4103/0976-500X.99426
20. Wu CL, Qiang L, Han W, Ming M, Viollet B, He YY. Role of AMPK in UVB-induced DNA damage repair and growth control. Oncogene 2012; 1-8; PMID:22751115; http://dx.doi.org/10.1038/ onc.2012.279
21. Chaudhary SC, Kurundkar D, Elmets CA, Kopelovich L, Athar M. Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway. Photochem Photobiol 2012; 88:1149-56; PMID:22540890; http://dx.doi.org/10.1111/j.1751-1097.2012.01165.x
22. Martin M, Marais R. Metformin: a diabetes drug for cancer, or a cancer drug for diabetics? J Clin Oncol 2012; 30:2698-700; PMID:22565000; http://dx.doi. org/10.1200/JCO.2012.42.1677
23. Misso ML, Teede HJ, Hart R, Wong J, Rombauts L, Melder AM, et al. Status of clomiphene citrate and metformin for infertility in PCOS. Trends Endocrinol Metab 2012; 23:533-43; PMID:22939889; http:// dx.doi.org/10.1016/j.tem.2012.07. 001
24. Hirsch A, Hahn D, Kempna P, Hofer G, Nuoffer JM, Mullis PE, et al. Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain. Endocrinology 2012; 153:4354-66; PMID:22778212; http://dx.doi.org/10.1210/en. 2012-1145
25. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50:81-98; PMID:21241070; http://dx.doi. org/10.2165/11534750-000000000-00000
26. Mani H, Levy MJ, Davies MJ, Morris DH, Gray LJ, Bankart J, et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome; a 20 years retrospective cohort study. Clin Endocrinol (Oxf ) 2012; In press; PMID:23046078; http://dx.doi.org/10.1111/ cen.12068
27. Fiehn C. Methotrexate transport mechanisms: the basis for targeted drug delivery and s-folate-receptor-specific treatment. Clin Exp Rheumatol 2010; 28(Suppl 61):S40-5; PMID:21044432
28. Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, Iversen L, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish realworld cohort study. J Intern Med 2013; 273:197-204; PMID:22963528
29. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 7(Suppl 1):332-9; PMID:19630828; http://dx.doi.org/10. 1111/j.1538-7836.2009.03404.x
30. Russo GT, Minutoli L, Bitto A, Altavilla D, Alessi E, Giandalia A, et al. Methotrexate Increases Skeletal Muscle GLUT4 Expression and Improves Metabolic Control in Experimental Diabetes. J Nutr Metab 2012; 2012:132056; PMID:22778921; http://dx.doi. org/10.1155/2012/132056
31. Zolk O. Disposition of metformin: variability due to polymorphisms of organic cation transporters. Ann Med 2012; 44:119-29; PMID:21366511; http:// dx.doi.org/10.3109/07853890.2010.549144
32. Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 2007; 35:1956-62; PMID:17600084; http://dx.doi. org/10.1124/dmd.107.015495
33. Damme K, Nies AT, Schaeffeler E, Schwab M. Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. Drug Metab Rev 2011; 43:499-523; PMID:21923552; http://dx.doi.org/10.3109/036025 32.2011.602687
34. Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology (Oxford) 2010; 49:2337-45; PMID:20713496; http://dx.doi.org/10. 1093/rheumatology/ keq216
35. van Roon EN, van de Laar MA. Methotrexate bioavailability. Clin Exp Rheumatol 2010; 28(Suppl 61):S27-32; PMID:21044430
36. Chae JW, Baek IH, Lee BY, Cho SK, Kwon KI. Population PK/PD analysis of metformin using the signal transduction model. Br J Clin Pharmacol 2012; 74:815-23; PMID:22380769; http://dx.doi. org/10.1111/j.1365-2125.2012.04260.x
37. Robert F, Fendri S, Hary L, Lacroix C, Andrejak M, Lalau JD. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab 2003; 29:279-83; PMID:12909816; http://dx.doi.org/10.1016/S1262- 3636(07)70037-X
38. Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996; 36:1012-21; PMID:8973990; http:// dx.doi.org/10.1177/009127009603601105
39. Stepensky D, Friedman M, Raz I, Hoffman A. Pharmacokinetic- pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 2002; 30:861-8; PMID:12124302; http:// dx.doi.org/10.1124/dmd.30.8.861
40. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348:607-14; PMID:10839993; http://dx.doi.org/10.1042/0264-6021:3480607
41. Sogame Y, Kitamura A, Yabuki M, Komuro S. A comparison of uptake of metformin and phenformin mediated by hOCT1 in human hepatocytes. Biopharm Drug Dispos 2009; 30:476-84; PMID:19768675; http://dx.doi.org/10.1002/bdd.684
42. Davidoff F, Haas D. Phenethylbiguanide effect on mitochondrial Ca+ and Mg2+ content. Biochem Pharmacol 1979; 28:3457-63; PMID:394746; http:// dx.doi.org/10.1016/0006-2952(79)90086-8
43. Chan ESL, Cronstein BN. Methotrexate-how does it really work? Nat Rev Rheumatol 2010; 6:175-8; PMID:20197777; http://dx.doi.org/10.1038/ nrrheum.2010.5
44. Baggott JE, Morgan SL, Sams WM, Linden J. Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol 1999; 135:813-7; PMID:10411156; http:// dx.doi.org/10.1001/archderm.135.7.813
45. Hiratsuka C, Fukuwatari T, Shibata K. Fate of dietary tryptophan in young Japanese women. Int J Tryptophan Res 2012; 5:33-47; PMID:23150724
46. Huo T, Cai S, Lu X, Sha Y, Yu M, Li F. Metabonomic study of biochemical changes in the serum of type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J Pharm Biomed Anal 2009; 49:976-82; PMID:19249171; http://dx.doi. org/10.1016/j.jpba.2009.01.008
47. Marchetti P, Masiello P, Benzi L, Cecchetti P, Fierabracci V, Giannarelli R, et al. Effects of metformin therapy on plasma amino acid pattern in patients with maturityonset diabetes. Drugs Exp Clin Res 1989; 15:565-70; PMID:2637797
48. Song IS, Lee Y, Shin MH, Kim H, Ahn YG, Park I, et al. Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition. PLoS One 2012; 7:e36637; PMID:22590580; http://dx.doi. org/10.1371/journal.pone.0036637
49. Shen S, O'Brien T, Yap LM, Prince HM, McCormack CJ. The use of methotrexate in dermatology: a review. Australas J Dermatol 2012; 53:1-18; PMID:22309324; http://dx.doi.org/10.1111/j.1440-0960.2011.00839.x
50. Greasley SE, Horton P, Ramcharan J, Beardsley GP, Benkovic SJ, Wilson IA. Crystal structure of a bifunctional transformylase and cyclohydrolase enzyme in purine biosynthesis. Nat Struct Biol 2001; 8:402-6; PMID:11323713; http://dx.doi.org/10.1038/87555
51. Tibbetts AS, Appling DR. Compartmentalization of Mammalian folate-mediated one-carbon metabolism. Annu Rev Nutr 2010; 30:57-81; PMID:20645850; http://dx.doi.org/10.1146/annurev. nutr.012809.104810
52. Baggott JE, Tamura T. Evidence for the hypothesis that 10-formyldihydrofolate is the in vivo substrate for aminoimidazolecarboxamide ribotide transformylase. Exp Biol Med (Maywood) 2010; 235:271-7; PMID:20404044; http://dx.doi.org/10.1258/ ebm.2009.009151
53. Andersson SE, Johansson LH, Lexmuller K, Ekstrom GM. Anti-arthritic effect of methotrexate: is it really mediated by adenosine? Eur J Pharm Sci 2000; 9:333-43; PMID:10664473; http://dx.doi.org/10.1016/ S0928-0987(99)00073-1
54. Phillips DC, Woollard KJ, Griffiths HR. The antiinflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 2003; 138:501-11; PMID:12569075; http://dx.doi.org/10. 1038/ sj.bjp.0705054
55. Morgan SL, Oster RA, Lee JY, Alarcon GS, Baggott JE. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum 2004; 50:3104-11; PMID:15476202; http://dx.doi.org/10.1002/ art.20516
56. Beckers A, Organe S, Timmermans L, Vanderhoydonc F, Deboel L, Derua R, et al. Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside. Mol Cancer Ther 2006; 5:2211-7; PMID:16985054; http://dx.doi. org/10.1158/1535-7163.MCT-06-0001
57. Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 2009; 69:5467-74; PMID:19549896; http://dx.doi.org/10.1158/0008-5472.CAN-08-4979
58. Rothbart SB, Racanelli AC, Moran RG. Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res 2010; 70:10299-309; PMID:21159649; http://dx.doi.org/10.1158/0008-5472.CAN-10-1873
59. Kuznetsov JN, Leclerc GJ, Leclerc GM, Barredo JC. AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia. Mol Cancer Ther 2011; 10:437-47; PMID:21262957; http://dx.doi.org/10.1158/1535-7163.MCT-10-0777
60. Yao SYM, Ng AML, Cass CE, Baldwin SA, Young JD. Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J Biol Chem 2011; 286:32552-62; PMID:21795683; http://dx.doi. org/10.1074/jbc.M111.236117
61. Griffiths HR, Dunston CR, Bennett SJ, Grant MM, Phillips DC, Kitas GD. Free radicals and redox signalling in T-cells during chronic inflammation and ageing. Biochem Soc Trans 2011; 39:1273-8; PMID:21936801; http://dx.doi.org/10. 1042/BST0391273
62. Gregori-Puigjane E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, et al. Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A 2012; 109:11178-83; PMID:22711801; http://dx.doi. org/10.1073/pnas.1204524109
63. Cuthbertson DJ, Babraj JA, Mustard KJW, Towler MC, Green KA, Wackerhage H, et al. 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes 2007; 56:2078-84; PMID:17513706; http://dx.doi.org/10.2337/db06-1716
64. Boon H, Bosselaar M, Praet SFE, Blaak EE, Saris WHM, Wagenmakers AJM, et al. Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients. Diabetologia 2008; 51:1893-900; PMID:18709353;
65. Babraj JA, Mustard K, Sutherland C, Towler MC, Chen S, Smith K, et al. Blunting of AICAR-induced human skeletal muscle glucose uptake in type 2 diabetes is dependent on age rather than diabetic status. Am J Physiol Endocrinol Metab 2009; 296:E1042-8; PMID:19190259; http://dx.doi.org/10.1152/ ajpendo. 90811.2008
66. Paglia G, Hrafnsdottir S, Magnusdottir M, Fleming RMT, Thorlacius S, Palsson BO, et al. Monitoring metabolites consumption and secretion in cultured cells using ultra-performance liquid chromatography quadrupole-time of flight mass spectrometry (UPLCQ-ToF-MS). Anal Bioanal Chem 2012; 402:1183-98; PMID:22159369; http://dx.doi.org/10.1007/s00216-011-5556-4
67. Pressman BC. The Effects Energy of Guanidine and Alkylguanidines Transfer Reactions of Mitochondria. J Biol Chem 1963; 238:401-9
68. Davidoff F. Effects of guanidine derivatives on mitochondrial function. Ca2+ uptake and release. J Biol Chem 1974; 249:6406-15; PMID:4418697
69. Davidoff F. Effects of guanidine derivatives on mitochondrial function. II. Reversal of guanidine-derivative inhibiton by free fatty acids. J Clin Invest 1968; 47:2344-58; PMID:5676528; http://dx.doi. org/10.1172/JCI105919
70. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000; 275:223-8; PMID:10617608; http://dx.doi.org/10.1074/ jbc.275.1.223
71. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122:253-70; PMID:22117616; http://dx.doi. org/10.1042/CS20110386
72. Larsen S, Rabol R, Hansen CN, Madsbad S, Helge JW, Dela F. Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration. Diabetologia 2012; 55:443-9; PMID:22009334; http://dx.doi.org/10.1007/s00125-011-2340-0
73. Guigas B, Detaille D, Chauvin C, Batandier C, De Oliveira F, Fontaine E, et al. Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem J 2004; 382:877-84; PMID:15175014; http://dx.doi. org/10.1042/BJ20040885
74. Li B, Chauvin C, De Paulis D, De Oliveira F, Gharib A, Vial G, et al. Inhibition of complex I regulates the mitochondrial permeability transition through a phosphate-sensitive inhibitory site masked by cyclophilin D. Biochim Biophys Acta 2012; 1817:1628-34; PMID:22659400; http://dx.doi.org/10.1016/j. bbabio. 2012.05.011
75. Batandier C, Guigas B, Detaille D, El-Mir MY, Fontaine E, Rigoulet M, et al. The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 2006; 38:33-42; PMID:16732470; http:// dx.doi.org/10.1007/s10863-006-9003-8
76. Kaminski MM, Sauer SW, Klemke CD, Suss D, Okun JG, Krammer PH, et al. Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated immunosuppression. J Immunol 2010; 184:4827-41; PMID:20335530; http://dx.doi.org/10.4049/jimmunol. 0901662
77. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011; 13:1016-23; PMID:21892142; http://dx.doi.org/10.1038/ncb2329
78. Sweeney D, Raymer ML, Lockwood TD. Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents. Biochem Pharmacol 2003; 66:663-77; PMID:12906931; http://dx.doi. org/10.1016/S0006-2952(03)00338-1
79. Lockwood TD. The lysosome among targets of metformin: new anti-inflammatory uses for an old drug? Expert Opin Ther Targets 2010; 14:467-78; PMID:20392164; http://dx.doi.org/10.1517/14728221003774135
80. Lu LP, Yang P, Qin SD, Zhu ML. Bis[1,1-dimethylbiguanide(1-)-kappa2N2,N5] copper(II) monohydrate. Acta Crystallogr C 2004; 60:m219-20; PMID:15131370; http://dx.doi.org/10.1107/ S0108270104006729
81. Logie L, Harthill J, Patel K, Bacon S, Hamilton DL, Macrae K, et al. Cellular responses to the metal-binding properties of metformin. Diabetes 2012; 61:1423-33; PMID:22492524; http://dx.doi.org/10.2337/db11-0961
82. Rena G, Pearson ER, Sakamoto K. Molecular action and pharmacogenetics of metformin: current understanding of an old drug. Diabetes Management 2012; 2:439-52; http://dx.doi.org/10.2217/dmt.12.42
83. Lu L, Gao X, Zhu M, Wang S, Wu Q, Xing S, et al. Exploration of biguanido-oxovanadium complexes as potent and selective inhibitors of protein tyrosine phosphatases. Biometals 2012; 25:599-610; PMID:22547055; http://dx.doi.org/10.1007/s10534-012-9548-4
84. Holland W, Morrison T, Chang Y, Wiernsperger N, Stith BJ. Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol 2004; 67:2081-91; PMID:15135305; http://dx.doi.org/10.1016/j. bcp.2004.02.016
85. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13:251-62; PMID:22436748; http://dx.doi.org/10.1038/ nrm3311
86. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108:1167-74; PMID:11602624
87. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51:2074-81; PMID:12086935; http://dx.doi. org/10.2337/diabetes.51.7.2074
88. Boyle JG, Logan PJ, Jones GC, Small M, Sattar N, Connell JMC, et al. AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia 2011; 54:1799-809; PMID:21455728; http://dx.doi. org/10.1007/s00125-011-2126-4
89. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012; 336:918-22; PMID:22517326; http:// dx.doi.org/10.1126/ science.1215327
90. Zhang Y, Wang Y, Bao C, Xu Y, Shen H, Chen J, et al. Metformin interacts with AMPK through binding to ? subunit. Mol Cell Biochem 2012; 368:69-76; PMID:22644486; http://dx.doi.org/10.1007/s11010-012-1344-5
91. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006; 3:403-16; PMID:16753576; http:// dx.doi.org/10.1016/j.cmet.2006.05.005
92. Lee KH, Hsu EC, Guh JH, Yang HC, Wang D, Kulp SK, et al. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem 2011; 286:39247-58; PMID:21917926; http://dx.doi. org/10.1074/jbc. M111.264598
93. Ouyang J, Parakhia RA, Ochs RS. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 2011; 286:1-11; PMID:21059655; http:// dx.doi.org/10.1074/jbc.M110.121806
94. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 2012; 441:1-21; PMID:22168436; http://dx.doi.org/10.1042/ BJ20110892
95. Canto C, Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev 2012; 64:166-87; PMID:22106091; http://dx.doi. org/10.1124/pr.110.003905
96. Eigenbrodt E, Glossmann H. Glycolysis-one of the keys to cancer? Trends Pharmacol Sci 1980; 1:240-5; http://dx.doi.org/10.1016/0165-6147(80)90009-7
97. Kami?ski MM, Sauer SW, Kami?ski M, Opp S, Ruppert T, Grigaravi?ius P, et al. T cell activation is driven by an ADP-dependent glucokinase linking enhanced glycolysis with mitochondrial reactive oxygen species generation. Cell Rep 2012; 2:1300-15; PMID:23168256; http://dx.doi.org/10.1016/j.celrep.2012.10.009
98. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010; 11:390-401; PMID:20444419; http://dx.doi.org/10.1016/j. cmet.2010.03.014
99. Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A 2010; 107:21830-5; PMID:21098287; http://dx.doi. org/10.1073/pnas.0912793107
100. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011; 71:4366-72; PMID:21540236; http://dx.doi. org/10.1158/0008-5472.CAN-10-1769
101. Turban S, Stretton C, Drouin O, Green CJ, Watson ML, Gray A, et al. Defining the contribution of AMPactivated protein kinase (AMPK) and protein kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle cells. J Biol Chem 2012; 287:20088-99; PMID:22511782; http://dx.doi.org/10.1074/ jbc. M111.330746
102. Refsum H, Helland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving lowdose methotrexate treatment. Clin Pharmacol Ther 1989; 46:510-20; PMID:2582708; http://dx.doi. org/10.1038/clpt.1989.179
103. Hroch M, Chladek J, Simkova M, Vaneckova J, Grim J, Martinkova J. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol 2008; 22:19-24; PMID:18031504
104. Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP Jr. Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the National Health and Nutrition Examination Survey, 1999-006. Diabetes Care 2012; 35:327-33; PMID:22179958; http://dx.doi.org/10.2337/dc11- 1582
105. Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2003; 254:455-63; PMID:14535967; http://dx.doi.org/10.1046/j.1365-2796.2003.01213.x
106. de Jager J, Kooy A, Lehert P, Wulffele MG, van der Kolk J, Bets D, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010; 340:c2181; PMID:20488910; http:// dx.doi.org/10.1136/bmj.c2181
107. Aarsand AK, Carlsen SM. Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. J Intern Med 1998; 244:169-74; PMID:10095804; http://dx.doi. org/10.1046/j.1365-2796. 1998.00361.x
108. Carlsen SM, Folling I, Grill V, Bjerve KS, Schneede J, Refsum H. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest 1997; 57:521-7; PMID:9350072; http://dx.doi. org/10.3109/00365519709084603
109. Palomba S, Falbo A, Giallauria F, Russo T, Tolino A, Zullo F, et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care 2010; 33:246-51; PMID:19933994; http://dx.doi.org/10.2337/dc09- 1516
110. Corominas-Faja B, Quirantes-Pine R, Oliveras-Ferraros C, Vazquez-Martin A, Cufi S, Martin-Castillo B, et al. Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) 2012; 4:480-98; PMID:22837425
111. Zakikhani M, Bazile M, Hashemi S, Javeshghani S, Avizonis D, St Pierre J, et al. Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin. PLoS One 2012; 7:e49513; PMID:23185347; http://dx.doi.org/10.1371/journal.pone. 0049513
112. Nath N, Khan M, Paintlia MK, Singh I, Hoda MN, Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol 2009; 182:8005-14; PMID:19494326; http://dx.doi.org/10.4049/jimmunol. 0803563
113. Bai A, Ma AG, Yong M, Weiss CR, Ma Y, Guan Q, et al. AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem Pharmacol 2010; 80:1708-17; PMID:20797389; http://dx.doi.org/10.1016/j. bcp.2010.08.009
114. Park CS, Bang BR, Kwon HS, Moon KA, Kim TB, Lee KY, et al. Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinase. Biochem Pharmacol 2012; 84:1660-70; PMID:23041647; http://dx.doi.org/10.1016/j. bcp.2012.09.025
115. Sag D, Carling D, Stout RD, Suttles J. Adenosine 5'-monophosphate- activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 2008; 181:8633-41; PMID:19050283
116. Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010; 115:4742-9; PMID:20351312; http://dx.doi.org/10. 1182/blood-2009-10-249540
117. Krysiak R, Okopien B. Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose. Atherosclerosis 2012; 225:403-7; PMID:23107042; http://dx.doi.org/10.1016/j.atherosclerosis. 2012.09.034
118. Engler JR, Zannettino ACW, Bailey CG, Rasko JEJ, Hughes TP, White DL. OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica 2011; 96:213-20; PMID:20971815; http://dx.doi.org/10.3324/ haematol.2010.033290
119. Arai M, Uchiba M, Komura H, Mizuochi Y, Harada N, Okajima K. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. J Pharmacol Exp Ther 2010; 334:206-13; PMID:20371705; http:// dx.doi.org/10.1124/jpet.109.164970
120. Salt IP, Palmer TM. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opin Investig Drugs 2012; 21:1155-67; PMID:22694351
121. Charles MA, Morange P, Eschwege E, Andre P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 1998; 21:1967-72; PMID:9802752; http://dx.doi.org/10.2337/diacare.21.11.1967
122. Chakrabarti R. Hockin, Elisabeth D, Fearnley GR. Fibrinolytic effect of metformin in coronary-artery disease. Lancet 1965; 286:256-9; http://dx.doi. org/10.1016/S0140-6736(65)92383-4
123. Fontbonne A, Diouf I, Baccara-Dinet M, Eschwege E, Charles MA. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial. Diabetes Metab 2009; 35:385-91; PMID:19665415; http://dx.doi.org/10.1016/j.diabet. 2009.03.005
124. Lund SS, Tarnow L, Stehouwer CDA, Schalkwijk CG, Teerlink T, Gram J, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008; 158:631-41; PMID:18426821; http://dx.doi.org/10.1530/EJE-07-0815
125. Luque-Ramirez M, Escobar-Morreale HF. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. Horm Metab Res 2010; 42:815-20; PMID:20730705; http:// dx.doi.org/10.1055/s-0030-1262855
126. Lin YS, Tsai SJ, Lin MW, Yang CT, Huang MF, Wu MH. Interleukin-6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate-2 polymorphism. Am J Reprod Immunol 2011; 66:527-33; PMID:21801267; http:// dx.doi.org/10.1111/j.1600-0897.2011.01059.x
127. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006; 21:1426-31; PMID:16497699; http:// dx.doi.org/10.1093/humrep/del003
128. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 2009; 94:4938-45; PMID:19890022; http://dx.doi. org/10.1210/jc.2009-1674
129. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Ann Rev Pathol 2012; 7:385-422; http://dx.doi.org/10.1146/ annurev-pathol-011811-132448
130. Davidovici BB, Sattar N, Prinz JC, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130:1785-96; PMID:20445552; http://dx.doi. org/10.1038/jid.2010.103
131. Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 2012; 132:556-62; PMID:22113483; http://dx.doi. org/10.1038/jid.2011.365
132. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157:68-73; PMID:17553036; http://dx.doi.org/10.1111/j.1365-2133.2007.07986.x
133. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011; 147:419-24; PMID:21173301; http://dx.doi. org/10.1001/archdermatol.2010.370
134. Ford ES, Zhao G, Tsai J, Li C. Vitamin D and all-cause mortality among adults in USA: findings from the National Health and Nutrition Examination Survey Linked Mortality Study. Int J Epidemiol 2011; 40:998-1005; PMID:21266455; http://dx.doi.org/10.1093/ ije/dyq264
135. Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol 2012; 148:995-1000; PMID:22710320; http://dx.doi.org/10.1001/ archdermatol.2012.1401
136. Ahlehoff O. Psoriasis and Cardiovascular Disease: epidemiological studies. Dan Med Bull 2011; 58:B4347; PMID:22047936
137. Suarez-Farinas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 2012; 132:2552-64; PMID:22763790; http://dx.doi.org/10.1038/jid.2012.184
138. Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, Lowes MA, et al. Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core"pathogenesis of disease. PLoS One 2012; 7:e44274; PMID:22957057; http://dx.doi.org/10.1371/journal.pone.0044274
139. Farias MM, Achurra P, Boza C, Vega A, de la Cruz C. Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients. Obes Surg 2012; 22:877-80; PMID:22488682; http://dx.doi. org/10.1007/s11695-012-0646-8
140. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88:1242-7; PMID:18996858
141. Phung OJ, Sood NA, Sill BE, Coleman CI. Oral anti-diabetic drugs for the prevention of Type 2 diabetes. Diabet Med 2011; 28:948-64; PMID:21429006; http://dx.doi.org/10.1111/j.1464-5491.2011.03303.x
142. Phung OJ, Baker WL, Tongbram V, Bhardwaj A, Coleman CI. Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a metaanalysis. Ann Pharmacother 2012; 46:469-76; PMID:22474136; http://dx.doi.org/10.1345/ aph.1Q554
143. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403; PMID:11832527; http://dx.doi.org/10.1056/ NEJMoa012512
144. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-totreat analysis of the DPP/DPPOS. Diabetes Care 2012; 35:723-30; PMID:22442395; http://dx.doi. org/10.2337/dc11-1468
145. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al.; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142:611-9; PMID:15838067
146. Diabetes Prevention Program Research Group. Longterm safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012; 35:731-7; PMID:22442396; http://dx.doi.org/10.2337/dc11-1299
147. Suzuki J, Yoshimura T, Simeonova M, Takeuchi K, Murakami Y, Morizane Y, et al. Aminoimidazole carboxamide ribonucleotide ameliorates experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53:4158-69; PMID:22562518; http://dx.doi. org/10.1167/iovs.11-9323
148. Pollak M. Investigating Metformin for Cancer Prevention and Treatment:The End of the Beginning. Cancer Discovery 2012; 2:778-790;PMID:22926251
149. Emami Riedmaier A,Fisel P,Nies AT,Schaeffeler E, Schwab M. Metformin and cancer:from the old medicine cabinet to pharmacological pitfalls and prospects.Trends Pharmacol Sci 2013;34 ;126-35;PMID:23277337